

Information For the Use
L-Ornithine L-Aspartate (250mg) + Silymarin (70mg)

Hepalogyl 140 Tablet

L-Ornithine L-Aspartate (250 mg) + Silymarin (70 mg) Tablet

damage caused by alcohol or medications that may be toxic to the liver.

Description:

L-Ornithine L-Aspartate (LOLA) is an amino acid compound that plays a key role in the urea cycle, helping the liver detoxify ammonia and promote nitrogen metabolism. Silymarin, a flavonoid complex extracted from the seeds of the milk thistle (*Silybum marianum*), is known for its hepatoprotective properties, helping protect liver cells from toxins and supporting liver regeneration. This combination is beneficial for liver health, particularly in managing liver disorders, improving liver function, and reducing ammonia levels in the body.

Composition:

Each tablet contains:

- L-Ornithine L-Aspartate: 250 mg
- Silymarin: 70 mg

Indications:

L-Ornithine L-Aspartate (250 mg) + Silymarin (70 mg) tablet is indicated for:

- **Hepatic encephalopathy:** To help reduce ammonia levels in the blood and improve cognitive function.
- **Liver disorders:** To support liver function and regeneration in conditions like cirrhosis, hepatitis, and fatty liver disease (NAFLD/NASH).
- **Liver detoxification:** To aid in detoxifying the liver and improving overall liver health.
- **Chronic alcohol use and medication-induced liver damage:** To mitigate liver

Dosage and Administration:

Adults:

- **Usual dose:** 1 tablet (250 mg L-Ornithine L-Aspartate + 70 mg Silymarin) taken 2-3 times a day, preferably after meals or as directed by a healthcare provider.
- The dose may vary based on the patient's condition and clinical response.

Route of Administration:

- The tablets should be swallowed whole with water.
- Do not crush or chew the tablets, as this may affect their efficacy.

Contraindications:

- **Hypersensitivity to any component of the formulation, including L-Ornithine L-Aspartate, Silymarin, or other excipients in the tablet.**
- **Severe renal impairment:** Use with caution in patients with renal dysfunction as both components may have renal implications.
- **Pregnancy:** The safety of this combination during pregnancy has not been fully established, so it should only be used if absolutely necessary and prescribed by a healthcare provider.
- **Breastfeeding:** There is limited information on whether this combination passes into breast milk, so use should be avoided unless deemed necessary by a doctor.

- **Severe liver failure with no potential for regeneration:** This formulation is not suitable for patients with end-stage liver failure where recovery or regeneration is not possible.
-

- **Store the tablets at room temperature (below 25°C), away from light and moisture.**
 - **Keep the container tightly closed and out of reach of children.**
 - **Do not use the product after the expiration date printed on the packaging.**
-

Warnings and Precautions:

- **Hepatic disorders:** Monitor liver function regularly in patients with liver disease to ensure therapeutic efficacy and prevent potential complications.
 - **Renal function:** Use with caution in patients with renal impairment. Regular monitoring of kidney function is recommended.
 - **Allergic reactions:** Although rare, allergic reactions (e.g., rash, itching, or anaphylaxis) can occur. Discontinue the medication if any signs of a severe allergic reaction appear.
 - **Use in elderly:** In elderly patients, lower doses may be required, and liver and kidney function should be monitored regularly.
 - **Prolonged use:** While beneficial for liver regeneration, long-term use should be monitored by healthcare providers.
-

Note:

L-Ornithine L-Aspartate (250 mg) + Silymarin (70 mg) tablet is a prescription-only medication and should be taken according to a healthcare provider's instructions. Regular liver function tests may be required to monitor the treatment's effectiveness, especially in patients with pre-existing liver conditions.

Manufactured in India for:



Cafoli Lifecare Pvt. Ltd.

(An ISO 9001: 2015 Certified Co.)

Plot no.: 367-FF, Industrial Area Phase-I,
Panchkula-134113

TM: Trademark Applied for

Side Effects:

- **Common:** Mild gastrointestinal discomfort (nausea, indigestion, or bloating), headache, or dizziness.
 - **Less common:** Skin rash, mild allergic reactions, or mild abdominal discomfort.
 - **Serious:** Rare cases of severe allergic reactions (e.g., anaphylaxis), liver enzyme abnormalities, or hepatotoxicity. If any severe side effects occur, discontinue use and seek immediate medical attention.
-

Storage: